Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis
Objective To evaluate the efficacy and safety of antiviral antibody therapies and blood
products for the treatment of novel coronavirus disease 2019 (covid-19). Design Living …
products for the treatment of novel coronavirus disease 2019 (covid-19). Design Living …
[HTML][HTML] Epidemiological and clinical characteristics of COVID-19 in children: a systematic review and meta-analysis
B Li, S Zhang, R Zhang, X Chen, Y Wang… - Frontiers in …, 2020 - frontiersin.org
Given the relatively low rate and limited publicly available data regarding children with
SARS-CoV-2 infection, this knowledge gap should be addressed with urgency. This …
SARS-CoV-2 infection, this knowledge gap should be addressed with urgency. This …
Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)
Objective To investigate the effectiveness of using convalescent plasma to treat moderate
coronavirus disease 2019 (covid-19) in adults in India. Design Open label, parallel arm …
coronavirus disease 2019 (covid-19) in adults in India. Design Open label, parallel arm …
[HTML][HTML] Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial
The efficacy of convalescent plasma for coronavirus disease 2019 (COVID-19) is unclear.
Although most randomized controlled trials have shown negative results, uncontrolled …
Although most randomized controlled trials have shown negative results, uncontrolled …
[HTML][HTML] Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial
RECOVERY Collaborative Group - Lancet (London, England), 2021 - ncbi.nlm.nih.gov
Background Many patients with COVID-19 have been treated with plasma containing anti-
SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent …
SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent …
[HTML][HTML] Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection
A Gharbharan, CCE Jordans… - Nature …, 2021 - nature.com
In a randomized clinical trial of 86 hospitalized COVID-19 patients comparing standard care
to treatment with 300mL convalescent plasma containing high titers of neutralizing SARS …
to treatment with 300mL convalescent plasma containing high titers of neutralizing SARS …
[PDF][PDF] Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset
SP Anand, J Prévost, M Nayrac… - Cell Reports …, 2021 - cell.com
With the recent approval of highly effective coronavirus disease 2019 (COVID-19) vaccines,
functional and lasting immunity to severe acute respiratory syndrome coronavirus 2 (SARS …
functional and lasting immunity to severe acute respiratory syndrome coronavirus 2 (SARS …
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
RECOVERY Collaborative Group, PW Horby… - MedRxiv, 2021 - medrxiv.org
Background Treatment of COVID-19 patients with plasma containing anti-SARS-CoV-2
antibodies may have a beneficial effect on clinical outcomes. We aimed to evaluate the …
antibodies may have a beneficial effect on clinical outcomes. We aimed to evaluate the …
[HTML][HTML] Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial
O Abani, A Abbas, F Abbas, M Abbas, S Abbasi… - The Lancet, 2021 - thelancet.com
Background Many patients with COVID-19 have been treated with plasma containing anti-
SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent …
SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent …
[HTML][HTML] A systematic review of systematic reviews on the COVID-19 pandemic
ZN Hatmi - SN comprehensive clinical medicine, 2021 - Springer
COVID-19 a systemic inflammation involving multiple organs, affecting all age groups, with
high mortality rate, severe adverse outcomes, and high economic burden need to be …
high mortality rate, severe adverse outcomes, and high economic burden need to be …
